December 10, 2014
Celgene K.K. announced on December 9 that the efficacy of Revlimid (lenalidomide) was confirmed in a PII clinical study in treatment-naïve multiple myeloma patients. The PII study of lenalidomide is a multi-center, single-group, open-label study in which lenalidomide was administered...read more